FAS and ovarian cancer: This has led to studies targeting FAS for inhibition in tumor models, such as in ovarian cancer, where inhibition of FAS resulted in activation of the AMPK pathway and subsequent cytotoxicity in the SKOV3 human ovarian cancer cell line (64).